Posted by Michael Wonder on 18 Jul 2024
Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (review of previous guidance)
16 July 2024 - The Department of Health and Social Care has asked the NICE to review the guidance on the use of teclistamab in the NHS in England.
Teclistamab is recommended as an option for the treatment of adults with relapsed and refractory multiple myeloma after three or more treatments (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on their last treatment.
